These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7774654)

  • 1. Covalent linkage of C3 to properdin during complement activation.
    Whiteman LY; Purkall DB; Ruddy S
    Eur J Immunol; 1995 May; 25(5):1481-4. PubMed ID: 7774654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
    Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A covalent dimer of complement C4b serves as a subunit of a novel C5 convertase that involves no C3 derivatives.
    Masaki T; Matsumoto M; Yasuda R; Levine RP; Kitamura H; Seya T
    J Immunol; 1991 Aug; 147(3):927-32. PubMed ID: 1861081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of activated properdin with complexes of properdin with C3.
    Whiteman LY; Purkall DB; Ruddy S
    J Immunol; 1991 Aug; 147(4):1344-51. PubMed ID: 1869827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W; Schmidt G; Lynen R; Dieminger L
    J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
    Takata Y; Tamura N; Fujita T
    J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
    Brade V; Bentley C; Bitter-Suermann D; Hadding U
    Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of anticomplementary substances on properdin in normal and C2-deficient sera.
    McLean RH; Townsend K; Michael AF
    Clin Exp Immunol; 1975 Mar; 19(3):435-44. PubMed ID: 1204244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of immune precipitation by purified components of the alternative pathway.
    Naama JK; Holme E; Hamilton E; Whaley K
    Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin.
    Götze O; Medicus RG; Müller-Eberhard HJ
    J Immunol; 1977 Feb; 118(2):525-32. PubMed ID: 839069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
    Arnaout MA; Davis AE; Rosen RS; Alper CA
    J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
    Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
    J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An inherited deficiency of the third component of complement, C3, in guinea pigs.
    Burger R; Gordon J; Stevenson G; Ramadori G; Zanker B; Hadding U; Bitter-Suermann D
    Eur J Immunol; 1986 Jan; 16(1):7-11. PubMed ID: 3512275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.